New Treatment Addressing the Pathogenesis of Psoriasis

Psoriasis is an immune cell-mediated inflammatory skin disease. The interleukin (IL)23/IL17 axis plays an important role in the development of psoriasis. The effectiveness of biologic treatments such as tumor necrosis factor (TNF)α inhibitors (infliximab, adalimumab, certolizumab pegol), IL23 inhibi...

Full description

Bibliographic Details
Main Authors: Michio Tokuyama, Tomotaka Mabuchi
Format: Article
Language:English
Published: MDPI AG 2020-10-01
Series:International Journal of Molecular Sciences
Subjects:
Online Access:https://www.mdpi.com/1422-0067/21/20/7488
id doaj-94cdf9c402da400eb5ed745fc566ea94
record_format Article
spelling doaj-94cdf9c402da400eb5ed745fc566ea942020-11-25T03:40:32ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672020-10-01217488748810.3390/ijms21207488New Treatment Addressing the Pathogenesis of PsoriasisMichio Tokuyama0Tomotaka Mabuchi1Department of Dermatology, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa 259-1193, JapanDepartment of Dermatology, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa 259-1193, JapanPsoriasis is an immune cell-mediated inflammatory skin disease. The interleukin (IL)23/IL17 axis plays an important role in the development of psoriasis. The effectiveness of biologic treatments such as tumor necrosis factor (TNF)α inhibitors (infliximab, adalimumab, certolizumab pegol), IL23 inhibitors (ustekinumab, guselkumab, tildrakizumab, risankizumab), and IL17 inhibitors (secukinumab, ixekizumab, brodalumab) have verified these findings. Immune-related cells such as dendritic cells (DCs) and macrophages, in addition to Toll-like receptors and cytokines such as interferon (IFN)α, TNFα, IFNɤ, IL12, IL22, IL23, and IL17, are related to the pathogenesis of psoriasis. Here, we first review new insights regarding the pathogenesis of psoriasis, as it relates to DCs, Langerhans cells, macrophages, the signal transducer and activator of transcription 3 pathway, and aryl hydrocarbon receptor in cutaneous vascular endothelial cells. Based on these findings, we summarize currently available oral treatments and biologics. Furthermore, we describe a new treatment option including Janus kinase inhibitor, tyrosine kinase 2 inhibitor, modulator of sphingosine 1-phosphate receptor 1, and Rho-associated kinase 2 inhibitor.https://www.mdpi.com/1422-0067/21/20/7488psoriasisnew treatmentpathogenesisdendritic cellsJanus kinase inhibitorsphingosine 1-phosphate receptor 1
collection DOAJ
language English
format Article
sources DOAJ
author Michio Tokuyama
Tomotaka Mabuchi
spellingShingle Michio Tokuyama
Tomotaka Mabuchi
New Treatment Addressing the Pathogenesis of Psoriasis
International Journal of Molecular Sciences
psoriasis
new treatment
pathogenesis
dendritic cells
Janus kinase inhibitor
sphingosine 1-phosphate receptor 1
author_facet Michio Tokuyama
Tomotaka Mabuchi
author_sort Michio Tokuyama
title New Treatment Addressing the Pathogenesis of Psoriasis
title_short New Treatment Addressing the Pathogenesis of Psoriasis
title_full New Treatment Addressing the Pathogenesis of Psoriasis
title_fullStr New Treatment Addressing the Pathogenesis of Psoriasis
title_full_unstemmed New Treatment Addressing the Pathogenesis of Psoriasis
title_sort new treatment addressing the pathogenesis of psoriasis
publisher MDPI AG
series International Journal of Molecular Sciences
issn 1661-6596
1422-0067
publishDate 2020-10-01
description Psoriasis is an immune cell-mediated inflammatory skin disease. The interleukin (IL)23/IL17 axis plays an important role in the development of psoriasis. The effectiveness of biologic treatments such as tumor necrosis factor (TNF)α inhibitors (infliximab, adalimumab, certolizumab pegol), IL23 inhibitors (ustekinumab, guselkumab, tildrakizumab, risankizumab), and IL17 inhibitors (secukinumab, ixekizumab, brodalumab) have verified these findings. Immune-related cells such as dendritic cells (DCs) and macrophages, in addition to Toll-like receptors and cytokines such as interferon (IFN)α, TNFα, IFNɤ, IL12, IL22, IL23, and IL17, are related to the pathogenesis of psoriasis. Here, we first review new insights regarding the pathogenesis of psoriasis, as it relates to DCs, Langerhans cells, macrophages, the signal transducer and activator of transcription 3 pathway, and aryl hydrocarbon receptor in cutaneous vascular endothelial cells. Based on these findings, we summarize currently available oral treatments and biologics. Furthermore, we describe a new treatment option including Janus kinase inhibitor, tyrosine kinase 2 inhibitor, modulator of sphingosine 1-phosphate receptor 1, and Rho-associated kinase 2 inhibitor.
topic psoriasis
new treatment
pathogenesis
dendritic cells
Janus kinase inhibitor
sphingosine 1-phosphate receptor 1
url https://www.mdpi.com/1422-0067/21/20/7488
work_keys_str_mv AT michiotokuyama newtreatmentaddressingthepathogenesisofpsoriasis
AT tomotakamabuchi newtreatmentaddressingthepathogenesisofpsoriasis
_version_ 1724534153131589632